Form 4 Filing for Coherus Oncology, Inc.

Jill O'Donnell-Tormey, a director at Coherus Oncology, Inc., acquired 30,000 shares of Common Stock through restricted stock units (RSUs) on June 5, 2026. These RSUs will vest in full on the one-year anniversary of June 3, 2026, contingent upon her continued service. Additionally, she was granted stock options to purchase 60,000 shares of Common Stock, with an exercise price of $1.45 per share. These options will become fully exercisable on June 3, 2027, also subject to her continued service with the company. Both the RSUs and the stock options are reported as direct holdings.